Ultime notizie per Turning Point Brands (NYSE:TPB) Azioni

Turning Point Brands

Turning Point Brands Inc operates as manufacturer, marketer, provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in three segments namely Zig-Zag products; Stoker's products and NewGen products. The company generates maximum revenue from the Zig-Zag products segment.

Turning Point Brands Inc

BETMAKERS TECH GRP LTD by Betmakers Technology Group Ltd.

BetMakers Technology Group Ltd

RBC Capital analyst Greg Pardy maintains Imperial Oil (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#TSX">IMO</a>) with a Sector Perform and raises the price target from C$99 to C$101.

News

Price Target

Analyst Ratings

TSX:IMO

RBC Capital Maintains Sector Perform on Imperial Oil, Raises Price Target to C$101

RBC Capital analyst Jimmy Shan maintains InterRent REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IIP#TSX">IIP</a>) with a Outperform and lowers the price target from C$16.5 to C$15.

TSX:IIP

TSX:IIP/UN

RBC Capital Maintains Outperform on InterRent REIT, Lowers Price Target to C$15

CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)&nbsp;reported third-quarter sales of $95.43 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $92.75 billion</a>.&nbsp;
Total revenues increased 6.3%, primarily driven by growth in the Health Care Benefits and Pharmacy &amp; Consumer Wellness segments, partially offset by a decline in the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769047/cvs-health-corporation-reports-third-quarter-2024-results" rel="noreferrer noopener">Health Services segment</a>.
Adjusted EPS of $1.09 (inline with preliminary guidance of $1.05-$1.10) decreased from $2.21 in the prior year, missing the consensus of $1.53. The fall was primarily due to a decline in the Health Care Benefits segment&#8217;s operating results, which reflects continued utilization pressure and premium deficiency reserves of approximately $1.1 billion, related to anticipated losses in the fourth quarter of 2024 within the Medicare and individual <a target="_blank" href="https://www.benzinga.com/news/24/11/41719665/cvs-health-q3-earnings-preview-can-the-company-overcome-recent-challenges" rel="noreferrer noopener">exchange product lines</a>.
Adjusted operating income decreased 77.5% to $2.55 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41429974/cigna-and-humana-revive-early-merger-talks-after-year-long-pause-as-medicare-cost-pressure-looms" rel="noreferrer noopener">Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms</a>
During the third quarter of 2024, CVS Health <a target="_blank" href="https://www.cvshealth.com/content/dam/enterprise/cvs-enterprise/pdfs/2024/Q3-2024-Earnings-Release.pdf" rel="noreferrer noopener">finalized</a> its restructuring plan and recorded restructuring charges of approximately $1.2 billion, including store impairment charges for additional retail pharmacy stores it plans to close in 2025.
Revenues in the Health Care Benefits segment increased 25.5% to $32.99 billion. The Medical benefit ratio increased to 95.2% from 85.7% a year ago. Medical membership reached 27.1 million.
Health Services segment revenues decreased 5.9% to $44.13 billion. Pharmacy claims processed decreased 16.5%.
Concurrently, CVS&nbsp;Health announced&nbsp;that Prem&nbsp;Shah will be Group President and responsible for the operational performance across CVS Caremark, CVS Pharmacy, and the company&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769048/cvs-health-announces-leadership-appointments" rel="noreferrer noopener">Healthcare Delivery businesses</a>.
In addition, the company appointed Steve Nelson&nbsp;as President of Aetna. Both appointments are effective today.
Pharmacy &amp; Consumer Wellness segment revenues increased 12.3% to $32.42 billion, primarily driven by increased prescription volume, including increased contributions from vaccinations and pharmacy drug mix.
In October, CVS Health appointed David Joyner as its new president and CEO, replacing&nbsp;Karen Lynch amid the company&#8217;s&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41398693/cvs-health-appoints-david-joyner-president-and-chief-executive-officer" rel="noreferrer noopener">ongoing financial struggles</a>.
The company also withdrew the 2024 guidance provided in the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo" rel="noreferrer noopener">second-quarter earnings release</a>.
Price Action:&nbsp;CVS stock is up 11.30% at $61.60&nbsp;at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41754167/why-is-astrazeneca-stock-sinking-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is AstraZeneca Stock Sinking On Tuesday?</a></li>
</ul>
Image via Shutterstock

Earnings

Large Cap

Guidance

Health Care

Movers

General

CVS Health Stock Jumps After Mixed Q3 Earnings, Takes $1.2 Billion Restructuring Charges Hit

RBC Capital analyst Irene Nattel maintains Pet Valu Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PET#TSX">PET</a>) with a Outperform and raises the price target from C$34 to C$35.

TSX:PET

RBC Capital Maintains Outperform on Pet Valu Hldgs, Raises Price Target to C$35

WIIM

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XPEV

Shares of US-listed Chinese stocks are trading higher after Donald Trump was elected president of the United States, which could raise concerns over potential tariffs and US-China tensions.

Wells Fargo analyst Stephen Baxter maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $195 to $205.

Wells Fargo Maintains Overweight on Tenet Healthcare, Raises Price Target to $205

Warren Buffett, one of the world&#8217;s most successful investors, has shared plenty of advice over his long career. But one <a href="https://www.benzinga.com/news/23/07/33245523/warren-buffetts-no-1-investing-rule-dont-lose-money-practical-advice-for-a-billionaire-but-can-regul">piece of advice</a> stands out as his top rule: &#8220;The first rule of investment is don&#8217;t lose money.&#8221; And if you ask about the second rule? &#8220;Don&#8217;t forget the first.&#8221; According to Buffett, that&#8217;s all you need to know.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">1. Warren Buffett "Rule no.1 is don't lose and the second rule is never forget rule 1." &#x1f410; <a href="https://t.co/x0hEOgxVJ4">pic.twitter.com/x0hEOgxVJ4</a>
&mdash; Oliver &#x7C; MMMT Wealth (CPA) (@MMMTwealth) <a href="https://twitter.com/MMMTwealth/status/1850983304167571542?ref_src=twsrc%5Etfw">October 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>
It might sound simple — even a bit obvious. After all, who wants to lose money? But Buffett's point is more profound than it might first appear. <a href="https://www.benzinga.com/news/24/09/41091380/warren-buffet-tells-investors-to-give-up-on-me-vs-stock-approach-what-tells-you-whether-you-should-k">His investment philosophy</a> is about protecting what you already have. If you lose a big chunk of your investment, you need a huge return just to get back to where you started.&nbsp;
For example, when a stock drops by a big margin, it requires an even greater gain just to get back to its original value. It's much easier to prevent these kinds of losses in the first place than to claw your way back from them.&nbsp;
Of course, saying &#8220;don't lose money&#8221; is easier than actually following through, especially with the ups and downs of the stock market. But there are practical strategies investors can use to help follow Buffett&#8217;s rule.
See Also: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a>
You lower the chance of suffering a significant loss on any one investment by <a href="https://www.benzinga.com/money/how-to-diversify-your-portfolio">distributing your funds over several stocks or sectors</a>. Your portfolio can still be balanced even if one or two stocks do not perform well.
Buffett is known for investing in businesses with <a href="https://www.benzinga.com/startups/24/10/41252767/warren-buffetts-timeless-advice-is-to-invest-in-stocks-that-youd-be-perfectly-happy-to-hold-if-the-m">strong fundamentals</a> that he believes will be successful for many years to come. He prefers companies with a competitive edge, solid management, and products people will continue to buy. Instead of chasing the cheapest stocks, he looks for good companies at reasonable prices.
The market can be a rollercoaster, and emotions like fear or greed often cause people to make costly mistakes. Buffett's approach is to stay calm when others are panicking and to make decisions based on logic, not emotion.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
It's worth noting that even Warren Buffett has lost money, and he has been open about what he thinks are his biggest investment mistakes. He has also stated that one of his worst missteps was purchasing Berkshire Hathaway, a textile company that was initially in decline. Nevertheless, Buffett has been successful over the long term despite these setbacks because he is focused on limiting losses and learning from his mistakes.
<h2 class="wp-block-heading">Alternative Opinions</h2>
On the other hand, some investors think that taking measured risks, even at the expense of occasional losses, is a necessary component of attaining sizable returns, even if Buffett&#8217;s advice to avoid losses is generally accepted. <a href="https://www.benzinga.com/personal-finance/24/06/39360926/diversification-thats-for-idiots-mark-cuban-slams-warren-buffetts-investment-strategy-i-think-bu">Mark Cuban, for example, once said</a>, &#8220;Diversification, that&#8217;s for idiots&#8221; and that &#8220;buy and hold is a crock of s&#x2A;&#x2A;&#x2A;.&#8221;
Plus, startups, emerging technologies, and high-growth companies often come with higher risk but also the potential for substantial gains — something that Buffett's cautious approach might miss.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

'The First Rule Of Investment Is Don't Lose,' Says Warren Buffett. The Second Rule? Don't Forget The First — 'That's All The Rules'

In the current session, SBA Comms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) is trading at $218.54, after a 4.30% drop. Over the past month, the stock fell by 7.45%, and in the past year, by 0.22%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1730906184_0.png" alt="Past Year Chart" />

<h3>A Look at SBA Comms P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
SBA Comms has a lower P/E than the aggregate P/E of 52.76 of the Specialized REITs industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730906184_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

SBAC

P/E Ratio Insights for SBA Comms

BITF

CLSK

COIN

HIVE

MARA

RIOT

Shares of crypto-linked stocks are trading higher amid strength in Bitcoin, which reached an all-time high during the US presidential election.

Wells Fargo analyst Stephen Baxter maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Equal-Weight and raises the price target from $395 to $400.

Wells Fargo Maintains Equal-Weight on HCA Healthcare, Raises Price Target to $400

Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight and lowers the price target from $43 to $30.

APLS

Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $30

RBC Capital analyst Pammi Bir maintains BTB Real Estate Investment Trust (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTB#TSX">BTB</a>) with a Sector Perform and raises the price target from C$3.5 to C$3.75.

TSX:BTB

RBC Capital Maintains Sector Perform on BTB Real Estate Investment Trust, Raises Price Target to C$3.75

Wells Fargo analyst Elyse Greenspan maintains American Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) with a Equal-Weight and lowers the price target from $77 to $76.

Wells Fargo Maintains Equal-Weight on American Intl Gr, Lowers Price Target to $76

On Tuesday, Exact Sciences Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss estimate of $0.20.</a>
The reported quarterly sales of $708.66 million missed the consensus <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41757648/exact-sciences-announces-third-quarter-2024-results" rel="noreferrer noopener">estimate of $717.66 million</a>.
Screening revenue was $545 million, an increase of 15%, and Precision Oncology&#8217;s revenue was $164 million, an increase of 5% on a reported and core revenue basis.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41185292/fda-clears-exact-sciences-next-generation-colorectal-cancer-diagnostic-test" rel="noreferrer noopener">FDA Clears Exact Sciences&#8217; Next-Generation Colorectal Cancer Diagnostic Test</a>.
&#8220;While we have made progress, our execution during the third quarter and updated outlook for the full year don&#8217;t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong,&#8221; said Kevin Conroy, chairman and CEO.
Guidance: Exact Sciences cuts its 2024 revenue guidance from $2.81 billion-$2.85 billion to $2.73 billion-$2.75 billion compared to the consensus of $2.832 billion.
The guidance includes a Screening sales forecast of $2.08 billion—$2.095 billion, compared to previous guidance of $2.155 billion—$2.175 billion.
Precision Oncology sales are expected to be $650 million- $655 million, down from prior guidance of $655 million &#8211; $675 million.
The company expects 2024 Adjusted EBITDA of $310 million—$320 million, down from previous guidance of $335 million—$355 million.
William Blair notes that management attributed the lower-than-expected guidance primarily to challenges affecting the screening segment.
While these explanations are logical, they raise questions about why certain factors weren&#8217;t identified or addressed sooner. Management, however, took full responsibility and conveyed a sincere commitment to improving performance, the analyst writes.
Despite these hurdles, the analyst remains optimistic about revenue growth in 2025, highlighting several factors within the company&#8217;s control.
William Blair emphasizes that investors will likely want to see clear signs of improved execution and revenue growth resuming in 2025.
With shares trading down, the analyst writes that valuation is at a compelling long-term entry point.
Price Action: At last check on Wednesday, EXAS stock was down 28.50% at $51.16.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41753865/apollos-fee-related-earnings-growth-sets-it-apart-in-alternative-assets-says-goldma" target="_blank" rel="noreferrer noopener">Apollo&#8217;s Fee-Related Earnings Growth Sets It Apart in Alternative Assets, Says Goldman Sachs With Bullish EPS Forecast</a></li>
</ul>

Analyst Color

Trading Ideas

EXAS

Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point

The ODP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODP#NASDAQ">ODP</a>) shares <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">are trading lower on Wednesday.</a>
The company reported third-quarter adjusted earnings per share of 71 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41769448/the-odp-corporation-announces-third-quarter-2024-results" rel="noreferrer noopener">missing the street view of $1.60.</a>
Quarterly sales of $1.780 billion, down 11% year-over-year, missed the analyst consensus of $1.820 billion.
The decrease in reported sales is largely related to lower sales in its Office Depot Division, primarily due to 53 fewer retail locations in service compared to the previous year and reduced transactions, as well as lower sales in its ODP Business Solutions Division.
&#8220;We&#8217;re leveraging our differentiated core strengths to pivot towards higher growth B2B opportunities, and we are beginning to see promising traction at both our ODP Business Solutions and Veyer Divisions,&#8221; said Gerry Smith, chief executive officer.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft" rel="noreferrer noopener">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a>
In the quarter under review, adjusted EBITDA was $62 million, compared to $138 million in the year-ago period.
As of September 28, ODP had total available liquidity of approximately $728 million, consisting of $192 million in cash and equivalents.
In a separate press release, the company announced a partnership with a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41769797/the-odp-corporation-embarks-on-a-new-10-year-1-5b-transformative-partnership-with-nationally-recog" rel="noreferrer noopener">nationally recognized strategic reseller</a>. This partnership, worth up to $1.5 billion spanning a 10-year period, will leverage the reseller provider&#8217;s expertise in creating custom, results-driven e-commerce solutions and the company&#8217;s extensive fulfillment centers and delivery network.
Outlook: ODP has <a target="_blank" href="https://www.theodpcorp.com/news-releases/news-release-details/odp-corporation-announces-second-quarter-2024-results" rel="noreferrer noopener">lowered </a>its full-year 2024 adjusted EPS guidance from a range of $4.25 &#8211; $5.00 to $3.10 &#8211; $3.80, below the $4.27 analyst estimate.
The company expects sales to be approximately $7 billion (prior view: at least $7 billion), compared to the $7.09 billion estimate.
Price Action: ODP shares are trading lower by 15.2% to $26.37 at last check Wednesday.
Photo via <a href="https://commons.wikimedia.org/wiki/File:Office_Depot_%284190699897%29.jpg">Wikimedia Commons</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy" target="_blank" rel="noreferrer noopener">Trump&#8217;s Historic Return: 7 Ways His Second Term Could Impact The US Economy</a></li>
</ul>

Equities

Office Depot's Parent Company ODP Slashes 2024 Outlook After Weak Q3 Earnings, Eyes B2B Pivot To Offset Retail Woes

Wells Fargo analyst Michael Brown maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Overweight and raises the price target from $149 to $164.

Wells Fargo Maintains Overweight on Apollo Global Management, Raises Price Target to $164

CRON

SNDL

TLRY

Shares of cannabis stocks are trading lower after a cannabis legalization initiative did not pass in Florida.

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he likes Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>).
On Tuesday, Broadcom expanded its multi-year partnership with Telia Company to advance Telia's modernization and transformation of telecom and cloud infrastructure using <a href="https://www.benzinga.com/markets/equities/24/11/41739196/broadcom-powers-telias-modernization-with-vmware-launches-ai-driven-velorain-more">VMware's product portfolio</a>.
SkyWater Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYT#NASDAQ">SKYT</a>) is a &#8220;very complicated story&#8221; as the company is losing a lot of money, Cramer said.
SkyWater Technology will report its fiscal third-quarter financial results following the close of the market on Thursday, Nov. 7.
IES Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) is a &#8220;really good&#8221; company, Cramer said. &#8220;I think you got a great stock there.&#8221;
On Sept. 26, IES Holdings announced the appointment of John Louis Fouts to its Board of Directors.
S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) is a buy, the &#8220;Mad Money&#8221; host said.
On Nov. 1, S&amp;P Global said it has completed the sale of its PrimeOne business to TS Imagine, a global, cross-asset provider of trading, portfolio, and risk management solutions for financial institutions.
Cramer recommended to buy more of Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) shares.
On Oct. 31, Merck reported third-quarter sales of $16.66 billion, up 4% year over year and beating the consensus estimate of $16.47 billion.
Price Action:
<ul>
<li>Broadcom shares gained 3.2% to settle at $173.90 on Tuesday.</li>
<li>SkyWater Technology shares fell 0.3% to close at $9.65 on Tuesday.</li>
<li>IES Holdings shares gained 3.3% to settle at $246.06 during the session.</li>
<li>S&amp;P Global gained 0.8% to settle at $489.71 on Tuesday.</li>
<li>Merck shares fell 0.2% to close at $101.65.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

AVGO

IESC

SKYT

SPGI

Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom

RBC Capital analyst Sabahat Khan maintains Boyd Group Services (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BYD#TSX">BYD</a>) with a Outperform and lowers the price target from C$280 to C$277.

TSX:BYD

RBC Capital Maintains Outperform on Boyd Group Services, Lowers Price Target to C$277

Wells Fargo analyst Neil Kalton maintains Fortis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTS#TSX">FTS</a>) with a Equal-Weight and raises the price target from C$59 to C$63.

TSX:FTS

Wells Fargo Maintains Equal-Weight on Fortis, Raises Price Target to C$63

Turning Point Brands (TPB) Q2 2024 Earnings Call Transcript

Maran Partners Fund Q2 2024 Letter

TPB: A Growth Nicotine And Cannabis-Adjacent Co. That Can Be A Share Buyback Machine

Craig-Hallum analyst Eric Des Lauriers assigned a Buy rating to the stock today. The company's shares closed last Friday at $36.62. According to Ti...

Craig-Hallum Gives a Buy Rating to Turning Point Brands (TPB)

Scott Fortune, an analyst from Roth MKM, has initiated a new Buy rating on Turning Point Brands (TPB). Scott Fortune has given his Buy rating due t...

Turning Point Brands (TPB): A Strong Buy on Growth and Market Expansion Potential

Dividend Champion, Contender, And Challenger Highlights: Week Of September 29

Pick Top Stocks Like Fantasy Football

Turning Point Brands: Why This Tobacco Stock Winner Has More Room To Run

Turning Point Brands: Growth In Disguise (Rating Upgrade)

Maran Partners Fund Q3 2024 Letter

AAPL

AMZN

BPOP

BVHMF

BVHMY

CADE

CFFI

CHCO

CHRW

CLAR

CMCSA

CSCO

CTBI

CTTOF

CTTPY

CUBE

DKNG

ERIE

FFIN

FISI

FMAO

FULT

FUNC

GAIN

GOOG

GOOGL

HBNC

HKHC

HLNE

HWBK

INDB

INGR

LRCX

MBIN

MORN

MSFT

NVDA

RGLD

SCVL

SFBS

SFNC

SKYW

SPTN

SWBI

SYBT

THFF

UBSI

UMBF

UTMD

VICI

VIRT

WASH

WSBC

Press Releases

Turning Point Brands Increases Common Stock Dividend

Turning Point Brands Appoints Andrew Flynn as Chief Financial Officer

Turning Point Brands to Host First Quarter 2024 Conference Call

Turning Point Brands Declares Common Stock Dividend

Turning Point Brands Announces First Quarter 2024 Results

Turning Point Brands to Host Second Quarter 2024 Conference Call

Turning Point Brands Announces Second Quarter 2024 Results

ZIG-ZAG LAUNCHES FOUR NEW FLAVORS OF 100% TOBACCO-FREE HEMP WRAPS

Turning Point Brands to Host Third Quarter 2024 Conference Call

British American Tobacco Industries, p.l.c. Common Stock ADR

British American Tobacco

Ispire Technology

Altria Group

Philip Morris International Inc Common Stock

Philip Morris Intl

RLX Technology Inc. American Depositary Shares, each representing the right to receive one (1) Class A ordinary share

Comments

Turning Point Brands

Notizie

Ultime notizie per Turning Point Brands (NYSE:TPB) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO